BUFFALO, NY — November 6, 2025 — A new research paper was published in Volume 16 of Genes & Cancer on October 31, 2025, titled “P3a site-specific and cassette mutagenesis for seamless protein, RNA and plasmid engineering.”

A cellular resistance mechanism at the origin of relapses of triple-negative breast cancer has recently been discovered by scientists from CNRS, Institut Curie and Université Paris Cité. Their findings have been published in Cancer Research, a journal of the American Association for Cancer Research, on 6 November 2025.

MUSC Hollings Cancer Center researcher Benjamin Toll, Ph.D., co-led a new American Association for Cancer Research (AACR) policy statement supporting a proposed FDA rule to cap nicotine levels in cigarettes. The proposed policy, still in the public comment stage, would reduce nicotine content by about 95%. By making cigarettes minimally or non-addictive, the policy could help millions of Americans quit smoking and prevent countless new addictions. Toll and his colleagues say the policy could save lives, reduce health care costs and transform cancer prevention, but emphasize the need to pair the policy with strong cessation support services and public education initiatives.

Metastasis remains the deadliest cancer complication, driven by circulating tumor cells (CTCs) that evade immune defenses in the bloodstream. A new review by scientists of China explores how CTCs interact with platelets, immune cells, and molecular pathways to survive, highlighting emerging therapeutic strategies and the evolving role of CTCs in liquid biopsy and metastasis prevention. The findings offer promising directions for advancing cancer diagnostics and anti-metastatic treatments.

Nearly half of all women aged younger than 40 who live with advanced breast cancer have children under the age of 18, according to the first global survey to investigate the challenges these women face. Results from the survey were presented to the Advanced Breast Cancer Eighth International Consensus Conference (ABC8) on Thursday.

People diagnosed with advanced breast cancer in 2025 can expect to live for an extra six or seven months, compared to the average survival time for patients diagnosed in 2011, according to a major study of patient data in the US presented at the Advanced Breast Cancer Eighth International Consensus Conference. Researchers say the increase in survival time coincides with the availability of more effective treatments for advanced breast cancer, as well as wider improvements in diagnosis and quality of care.

The ABC Global Alliance today launched the Advanced Breast Cancer (ABC) Global Decade Report 2015–2025 — a landmark global assessment revealing a decade of remarkable scientific progress that has transformed ABC care for some patients in some countries, while many others around the world have yet to benefit.